Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
17 percent of patients seeing neurologist travel long distance
Sep 13, 2023
Factors associated with long-distance travel include low neurologist density, rural setting and visits for ALS and nervous system cancer.